REN-related autosomal dominant tubulointerstitial kidney disease

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →

At a Glance

Live from database

1FDA treatments

1Recruiting trials

Regulatory Watchboard

10 events

May 2026Symptom Monitoring With Supported Feedback in Advanced Chronic Kidney Disease

Massachusetts General Hospital — NA

TrialNOT YET RECRUITING

Apr 2026Chronic Kidney Disease Associated Diet

Recep Tayyip Erdogan University Training and Research Hospital

TrialNOT YET RECRUITING

Apr 2026Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus

Vifor Fresenius Medical Care Renal Pharma — PHASE2

TrialRECRUITING

Apr 2026A Phase I Study Comparing the Safety, Pharmacokinetics and Renal Effects of VRP-034 and Marketed Polymyxin B in Healthy Volunteers

Venus Remedies Limited — PHASE1

TrialNOT YET RECRUITING

Mar 2026ID-ENTITY Trial- Evaluating Serial T-ID Monitoring

Transplant Genomics, Inc.

TrialNOT YET RECRUITING

Mar 2026MULTIMODAL APPROACH IN THE DIAGNOSIS OF SEPTIC AKI

Ankara Etlik City Hospital

TrialNOT YET RECRUITING

Feb 2026Prognostic Value of Novel Biomarkers on Adverse Renal Outcomes in High-Risk Cardiac Surgery Patients

Guowei Tu

TrialRECRUITING

Feb 2026Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD

University of Alberta

TrialNOT YET RECRUITING

Feb 2026Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate in Sepsis-Associated Acute Kidney Injury

Centre Hospitalier Universitaire de Nīmes — PHASE1, PHASE2

TrialNOT YET RECRUITING

Dec 2025A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)

Qilu Pharmaceutical Co., Ltd. — PHASE3

TrialNOT YET RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

1

Copay cards

Copay Assistance1

EXTRANEAL

Baxter

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Elitek

(rasburicase)Orphan drug

Sanofi-Synthelabo Research

12.1 Mechanism of Action In humans, uric acid is the final step in the catabolic pathway of purines. Rasburicase catalyzes enzymatic oxidation of poor...

Approved Jul 2002FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

1 active trial

1Unknown

1Total recruiting

Search clinical trials for REN-related autosomal dominant tubulointerstitial kidney disease →

Recent News & Research

No recent news articles indexed yet for REN-related autosomal dominant tubulointerstitial kidney disease.
Search PubMed for REN-related autosomal dominant tubulointerstitial kidney disease →

Browse all REN-related autosomal dominant tubulointerstitial kidney disease news →

Specialist Network

Top 6 by expertise

Marc A Judson, MD, MD

Medical University of South Carolina

📍 ALBANY, NY

Score 344 trials

Rebecca J Brown, M.D.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

📍 Bethesda, Maryland

Score 317 trials

Frédérique Menzaghi, PhD

Cara Therapeutics

Score 236 trials

Central Contact

Astellas Pharma Global Development

Score 1125 trials

General Manager

Tanabe Pharma Corporation

Score 314 trials6 pubs

Mohan Dr Ramchandani, MBBS MD

AIG Hospitals

Score 32 trials

View all REN-related autosomal dominant tubulointerstitial kidney disease specialists →

Quick Actions

View Disease Page

Full profile, treatments, community

Search Clinical Trials

Find recruiting studies now

Find Specialists

Ranked by expertise & trials

Financial Assistance

Copay cards, PAPs, grants

Latest News

Research, approvals & updates

Browse All Diseases

11,000+ rare disease profiles